Unlock instant, AI-driven research and patent intelligence for your innovation.

Cyanoaryl-aniline compounds for treatment of dermal disorders

A kind of compound and mixture technology, applied in the field of cyanoaromatic-aniline compounds for treating skin diseases

Pending Publication Date: 2021-10-01
NFLECTION THERAPEUTICS INC
View PDF40 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, clinical trials have shown side effects of MEK inhibitors used at high doses for prolonged periods of time

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cyanoaryl-aniline compounds for treatment of dermal disorders
  • Cyanoaryl-aniline compounds for treatment of dermal disorders
  • Cyanoaryl-aniline compounds for treatment of dermal disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0335] Example 1: 4-cyano-2-((2-fluoro-4-iodophenyl)amino)benzoic acid

[0336]

[0337] will be at -78°C in N 2 A stirred solution of 4-cyano-2-fluorobenzoic acid (3.0 g, 18.1 mmol) in THF (30 mL) was treated (dropwise) with LDA (2.0 M in THF, 27.2 mL, 54.5 mmol). After 20 min, a solution of 2-fluoro-4-iodoaniline (12.9 g, 54.5 mmol) in dry THF (15 mL) was added dropwise and the reaction mixture was continued to stir and allowed to warm to room temperature. After 16 h, the reaction mixture was concentrated in vacuo, acidified with 1M HCl and washed with Et 2 O extracted twice. The combined organic phases were washed with brine, washed with Na 2 SO 4 Dry, filter and concentrate in vacuo. The crude residue was purified by trituration in boiling DCM to give the product as a yellow solid (1.57 g, 22.7%). m / z 381.1[M-H] - . 1 H NMR (400MHz, DMSO-d 6 )δppm 13.91 (s, 1H), 9.74 (s, 1H), 8.04 (d, J = 8.2Hz, 1H), 7.77 (dd, J = 10.3, 2.0Hz, 1H), 7.58 (dt, J = 8.5, 1.3Hz, 1H...

Embodiment 2

[0338] Example 2: 4-cyano-2-((2-fluoro-4-iodophenyl)amino)benzoic acid

[0339]

[0340] A microwave vial was charged with 4-cyano-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (80% pure) (0.19 g, 0.4 mmol), 3-hydroxyazetidine Hydrochloride (0.07g, 0.6mmol), HATU (0.25g, 0.6mmol) and diisopropylethylamine (140μL, 0.8mmol) and N,N-dimethylformamide (6mL). The reaction mixture was stirred overnight at room temperature. The reaction was quenched with water and extracted with ethyl acetate. The organics were washed with water, brine and dried over sodium sulfate. The solvent was evaporated. The residue was purified by flash chromatography (12 g silica gel, 0-5% methanol in dichloromethane) and then by reverse phase HPLC (30-95% acetonitrile / water) to give the product as a light yellow solid (71 mg, 41%) . m / z 438.1[M+1] + . 1 H NMR(300MHz,DMSO-d6):δ8.97(s,1H),7.69-7.65(dd,J=1.2Hz and 0.9Hz,1H),7.55-7.47(m,2H),7.40(s,1H ),7.28-7.18(m,2H),5.80(s,1H),4.45(s,1H),4.35(t,J=7.6...

Embodiment 16

[0345] Example 16: N-(azetidin-3-ylmethoxy)-4-cyano-2-((2-fluoro-4-iodophenyl)amino)benzamide

[0346]

[0347] Step 1: 3-(((4-cyano-2-((2-fluoro-4-iodophenyl)amino)benzamido)oxy)methyl)azacycle Butyl-1-carboxylate tert-butyl ester

[0348] 4-cyano-2-((2-fluoro-4-iodophenyl)amino)benzoic acid (0.100 g, 0.3 mmol) in N,N-dimethylformamide (3 mL) was charged in a microwave vial ), tert-butyl 3-((aminooxy)methyl)azetidine-1-carboxylate (60% pure) (0.13g, 0.4mmol), HATU (0.15g, 0.4mmol) and diisopropyl Diethylethylamine (135 μL, 0.8 mmol. The reaction mixture was stirred overnight at room temperature. The reaction was quenched with water and extracted with ethyl acetate. The organics were washed with water, brine, and dried over sodium sulfate. The solvent was evaporated. The residue was subjected to flash chromatography (12 g silica gel, 0-70% ethyl acetate in hexane). Product fractions were collected and solvent removed to give a yellow oil (77 mg, 52%). m / z 565.2 [M-1] ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK, wherein the compound is according to formula (I) shown in the specification and wherein R1, R2, R2a, R3, R3a, and X are as described herein.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to U.S. Provisional Application No. 62 / 769,871, filed November 20, 2018, which is incorporated herein in its entirety for all purposes. [0003] Background of the invention [0004] Neurofibromatosis type 1 (NF1) occurs in about 1:3500 newborns and is one of the most common autosomal dominant single gene disorders affecting human neurological function. Clinically, NF1 disease is characterized by the presence of benign peripheral nerve tumors, termed neurofibromas, involving Schwann cells with biallelic mutations in the NF1 gene, as well as other neoplastic and nonneoplastic manifestations. See Jousma et al. Pediatr. Blood Cancer 62: 1709-1716, 2015. NF1 has been associated with several skin disorders, including cutaneous neurofibromas; plexiform neurofibromas; café au laitspot; and freckles of the armpits and groin. Cutaneous neurofibromas occur in more than 95 percent of people with NF1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/136A61K31/166A61K31/44A61P17/00
CPCA61P17/00A61K31/44A61K31/166A61K31/42A61K45/06A61K31/196A61K31/397A61K31/40A61K31/337C07C255/58C07D213/84C07C255/59C07D205/04C07D207/12C07D261/04C07D305/06
Inventor J·金凯德M·邓克顿
Owner NFLECTION THERAPEUTICS INC